Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience
- 7 July 2018
- journal article
- research article
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 54 (12) , 614-618
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung diseaseJournal of Cystic Fibrosis, 2017
- Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung diseaseJournal of Cystic Fibrosis, 2017
- Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyThe Lancet Respiratory Medicine, 2017
- Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysisThe Lancet Respiratory Medicine, 2016
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Cystic fibrosis in Europe: patients live longer but are we ready?European Respiratory Journal, 2015
- Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practiceExpert Review of Respiratory Medicine, 2015
- Pulmonary exacerbations in cystic fibrosisPediatric Pulmonology, 2004